On Wednesday, Canaccord Genuity initiated coverage of Hims & Hers Health, Inc. (NYSE:HIMS) stock, a telehealth company, with a Buy rating and a price target of $20.00. The firm highlighted the healthcare industry's resistance to digital disruption, which has left consumer experiences inefficient and outdated.
Hims & Hers, founded in 2017, was recognized for its successful approach in addressing health conditions such as hair loss and erectile dysfunction through digital health services, affordable products, and engaging marketing strategies.
The company notably benefited during the pandemic, with its subscriber count nearly doubling in 2021. Unlike many direct-to-consumer peers who experienced a post-pandemic downturn, Hims & Hers has maintained its growth trajectory. This is attributed to its systematic expansion into new health categories and a focus on vertical operations to support personalized products and efficient fulfillment.
In the past few years, Hims & Hers has broadened its offerings to include treatments in clinical dermatology, mental health, and weight loss. This diversification has helped the company amass over 1.5 million subscribers and reach a revenue run-rate of $1 billion in just seven years. The firm's strategic pricing adjustments aimed at expanding the subscriber base were also noted as a factor in the company's robust growth.
Canaccord's positive outlook on Hims & Hers is further supported by the company's strong fourth-quarter results, which led to a recent increase in stock value. The analysis concluded with the expectation of a bright long-term opportunity for Hims & Hers, driven by a growing online subscription revenue, expanding margins, and positive free cash flow.
InvestingPro Insights
In light of Canaccord Genuity's optimistic assessment of Hims & Hers Health, Inc. (NYSE:HIMS), InvestingPro data and tips provide additional insights into the company's financial health and market performance. The company's market capitalization stands at a solid $3.12 billion, indicating a significant presence in the healthcare sector. Despite not being profitable over the last twelve months, with a negative P/E ratio of -151.45, analysts from InvestingPro forecast a turnaround with net income expected to grow this year. This outlook is consistent with a substantial revenue growth of 65.49% in the last twelve months as of Q4 2023, showcasing the company's rapid expansion.
InvestingPro Tips highlight the company's strong return over the last three months, with a price total return of 72.42%, and an even more impressive six-month return of 134.33%, reflecting a large price uptick in the market. This performance is particularly noteworthy given that Hims & Hers operates with a moderate level of debt and has liquid assets that exceed its short-term obligations, positioning it well for sustained growth. Additionally, analysts predict that the company will be profitable this year, a significant milestone that may further enhance investor confidence.
For readers looking to delve deeper into Hims & Hers' financials and market potential, InvestingPro offers additional tips and metrics. To access these insights and strengthen your investment strategies, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With several more InvestingPro Tips available, investors can gain a comprehensive understanding of the company's prospects and make informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.